In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because :

1. A. Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages
2. B. Lymphocytes from patient's blood are grown in culture, outside the body.
3. C. Genetically engineered lymphocytes are not immortal cells.
4. D. Retroviral vector is introduced into these lymphocytes.

Attempt this NEET 2022 Biology question free — pick an option to reveal the correct answer and a step-by-step explanation. Then join NEET Mastery Quest to practise 15,000+ PYQ and 2027-syllabus questions.